NCT05139615 is a Phase 2 clinical trial of APD418 in Acute Heart Failure With Reduced Ejection Fraction, sponsored by Pfizer.

Who is sponsoring NCT05139615?

NCT05139615 is sponsored by Pfizer.

What drugs are being tested in NCT05139615?

Interventions in NCT05139615: APD418, APD418, Placebo.

What condition does NCT05139615 study?

NCT05139615 studies Acute Heart Failure With Reduced Ejection Fraction.

Is NCT05139615 still recruiting?

NCT05139615 is currently terminated. Last updated 9 November 2023.

Are results published for NCT05139615?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-11-09 · How we verify

NCT05139615

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

Terminated Phase 2 Results posted Last updated 9 November 2023

What this trial tests

Phase 2 trial testing APD418 in Acute Heart Failure With Reduced Ejection Fraction in 22 participants. Terminated before completion.

Timeline

28 December 2021

Primary endpoint
19 September 2022

19 September 2022

Quick facts

Lead sponsor	Pfizer
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	22
Start date	28 December 2021
Primary completion	19 September 2022
Estimated completion	19 September 2022
Sites	21 locations across Greece, Serbia, Germany, Poland, United States

Drugs / interventions tested

APD418 — full drug profile →
APD418 — full drug profile →
Placebo

Conditions studied

Acute Heart Failure With Reduced Ejection Fraction — all drugs for Acute Heart Failure With Reduced Ejection Fraction →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 85, any sex, with Acute Heart Failure With Reduced Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Part A: Change in Cardiac Index (CI) Measured by Right Heart Catheterization (RHC) From Baseline to End of Intravenous (IV) Infusion at 6 Hours Primary · Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)

Cardiac index (CI) is a hemodynamic parameter that relates the cardiac output (CO) from left ventricle in one minute to body surface area (BSA), thus relating heart performance to the body size of the participant. It was measured by RHC.

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.33	± 0.660
Cohort 1- Placebo	0.10	± 0.100
Cohort 2- 0.5 mg/kg/hr APD418	0.25	± 0.372
Cohort 2- Placebo	0.10	± 0.245

Part A: Change in Stroke Volume (SV), Left Ventricular End-Systolic Volume (LVESV) and Left Ventricular End-Diastolic Volume (LVEDV) Measured by Echocardiogram (ECHO) From Baseline to End of IV Infusion at 6 Hours Secondary · Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)

SV is the volume of blood pumped from the left ventricle per beat. LVESV is the volume of blood in the left ventricle at the end of contraction and at diastole. LVEDV is the amount of blood in the heart's left ventricle just before the heart contracts. All these parameters were measured by ECHO.

Stroke Volume

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	3.13	± 10.623
Cohort 1- Placebo	-0.80	± NA
Cohort 2- 0.5 mg/kg/hr APD418	5.94	± 10.183
Cohort 2- Placebo	-3.15	± 7.152

LVESV

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-11.05	± 22.837
Cohort 1- Placebo	4.10	± NA
Cohort 2- 0.5 mg/kg/hr APD418	8.28	± 25.689
Cohort 2- Placebo	8.92	± 29.804

LVEDV

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-7.92	± 15.531
Cohort 1- Placebo	3.30	± NA
Cohort 2- 0.5 mg/kg/hr APD418	14.20	± 31.021
Cohort 2- Placebo	7.30	± 38.006

Part A: Change in Stroke Volume Index (SVI) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours Secondary · Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)

SVI was calculated as stroke volume divided by BSA. This was measured by ECHO.

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	1.50	± 5.518
Cohort 1- Placebo	-0.30	± NA
Cohort 2- 0.5 mg/kg/hr APD418	2.62	± 4.615
Cohort 2- Placebo	-2.00	± 4.492

Part A: Change in Left Ventricular Ejection Fraction (LVEF) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours Secondary · Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)

LVEF is the central measure of left ventricular systolic function. LVEF is the fraction of chamber volume ejected in systole (stroke volume) in relation to the volume of the blood in the ventricle at the end of diastole (end-diastolic volume). This was measured by ECHO.

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	1.90	± 6.009
Cohort 1- Placebo	0.47	± 1.457
Cohort 2- 0.5 mg/kg/hr APD418	1.14	± 3.204
Cohort 2- Placebo	-1.68	± 0.900

Part A: Change in Fractional Shortening (FS) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours Secondary · Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)

FS was calculated by measuring the percentage reduction in left ventricular diameter during systole. This was measured by ECHO.

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-2.60	± 7.791
Cohort 1- Placebo	0.47	± 5.710
Cohort 2- 0.5 mg/kg/hr APD418	-1.55	± 1.924
Cohort 2- Placebo	-4.50	± 7.444

Part A: Change in Left Ventricular End-Systolic and Left Ventricular End-Diastolic Diameter Measured by ECHO From Baseline to End of IV Infusion at 6 Hours Secondary · Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)

Left ventricular end-systolic diameter and left ventricular end-diastolic diameter were measured using ECHO.

Left ventricular end-systolic diameter

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.10	± 0.361
Cohort 1- Placebo	-0.04	± 0.384
Cohort 2- 0.5 mg/kg/hr APD418	0.22	± 0.321
Cohort 2- Placebo	0.35	± 0.544

Left ventricular end-diastolic diameter

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-0.04	± 0.087
Cohort 1- Placebo	-0.02	± 0.098
Cohort 2- 0.5 mg/kg/hr APD418	0.15	± 0.363
Cohort 2- Placebo	0.16	± 0.243

Part A: Change in Left Ventricular Global Longitudinal Strain (LVGLS) and Left Ventricular Global Circumferential Strain (LVGCS) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours Secondary · Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)

Left ventricular global strain is the average strain of the cardiac chamber wall, where LVGLS presents longitudinal shortening as a percentage (change in length as a proportion to baseline length). LVGCS measures the chamber deformation along the circumference of the cardiac wall in a tangential xy-direction and similarly presents the circumferential shortening as a percentage. Both the parameters were measured by ECHO.

LVGLS

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.30	± NA
Cohort 1- Placebo	-1.10	± NA
Cohort 2- 0.5 mg/kg/hr APD418	1.10	± 1.337
Cohort 2- Placebo	-1.29	± 0.987

LVGCS

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-6.70	± NA
Cohort 2- 0.5 mg/kg/hr APD418	0.05	± 2.105
Cohort 2- Placebo	0.00	± 3.111

Part A: Change in CI Measured by RHC at 0.5, 1, 2, 3, 4 and 5 Hours During 6 Hour IV Infusion Secondary · Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4 and 5 hours of IV infusion

CI is a hemodynamic parameter that relates the CO from left ventricle in one minute to BSA, thus relating heart performance to the body size of the participant. It was measured by RHC.

0.5 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-0.05	± 0.252
Cohort 1- Placebo	0.27	± 0.379
Cohort 2- 0.5 mg/kg/hr APD418	0.10	± 0.167
Cohort 2- Placebo	-0.10	± 0.183

1 hour

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.35	± 0.252
Cohort 1- Placebo	0.27	± 0.379
Cohort 2- 0.5 mg/kg/hr APD418	0.06	± 0.112
Cohort 2- Placebo	0.05	± 0.208

2 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.45	± 0.370
Cohort 1- Placebo	0.13	± 0.058
Cohort 2- 0.5 mg/kg/hr APD418	0.11	± 0.104
Cohort 2- Placebo	-0.08	± 0.126

3 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.68	± 0.427
Cohort 1- Placebo	0.20	± 0.265
Cohort 2- 0.5 mg/kg/hr APD418	0.20	± 0.279
Cohort 2- Placebo	0.15	± 0.129

4 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.25	± 0.100
Cohort 1- Placebo	0.10	± 0.100
Cohort 2- 0.5 mg/kg/hr APD418	0.09	± 0.221
Cohort 2- Placebo	0.10	± 0.346

5 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.23	± 0.457
Cohort 1- Placebo	0.17	± 0.153
Cohort 2- 0.5 mg/kg/hr APD418	0.11	± 0.274
Cohort 2- Placebo	0.08	± 0.096

Part A: Change in Cardiac Output (CO) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours Secondary · Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion

Change in CO measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure.

0.5 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-0.15	± 0.420
Cohort 1- Placebo	0.63	± 0.777
Cohort 2- 0.5 mg/kg/hr APD418	0.20	± 0.329
Cohort 2- Placebo	-0.15	± 0.300

1 hour

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.68	± 0.457
Cohort 1- Placebo	0.67	± 0.907
Cohort 2- 0.5 mg/kg/hr APD418	0.15	± 0.230
Cohort 2- Placebo	0.13	± 0.340

2 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.90	± 0.876
Cohort 1- Placebo	0.43	± 0.231
Cohort 2- 0.5 mg/kg/hr APD418	0.21	± 0.212
Cohort 2- Placebo	-0.08	± 0.189

3 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	1.28	± 0.877
Cohort 1- Placebo	0.47	± 0.643
Cohort 2- 0.5 mg/kg/hr APD418	0.41	± 0.568
Cohort 2- Placebo	0.33	± 0.299

4 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.43	± 0.222
Cohort 1- Placebo	0.27	± 0.231
Cohort 2- 0.5 mg/kg/hr APD418	0.18	± 0.467
Cohort 2- Placebo	0.20	± 0.560

5 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.43	± 0.911
Cohort 1- Placebo	0.43	± 0.379
Cohort 2- 0.5 mg/kg/hr APD418	0.25	± 0.559
Cohort 2- Placebo	0.15	± 0.191

6 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.75	± 1.420
Cohort 1- Placebo	0.30	± 0.346
Cohort 2- 0.5 mg/kg/hr APD418	0.53	± 0.742
Cohort 2- Placebo	0.23	± 0.499

Part A: Change in Pulmonary Capillary Wedge Pressure (PCWP), Right Atrial Pressure (RAP), Systolic Pulmonary Arterial Pressure/Diastolic Pulmonary Arterial Pressure (PAS/PAD) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours Secondary · Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion

PCWP estimated the left atrial pressure and was the pressure measured by wedging a pulmonary artery catheter with an inflated balloon into a small pulmonary arterial branch. PCWP was assessed by 2 successive measurements at least 10 minutes apart. RAP is the blood pressure in the right atrium of the heart. Change in PCWP, RAP, PAS/PAD at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure. All the parameters were measured by RHC.

PCWP: 0.5 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	1.50	± 2.887
Cohort 1- Placebo	0.67	± 3.055
Cohort 2- 0.5 mg/kg/hr APD418	-0.78	± 3.456
Cohort 2- Placebo	-2.67	± 4.726

PCWP: 1 hour

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-0.25	± 8.808
Cohort 1- Placebo	-2.33	± 4.041
Cohort 2- 0.5 mg/kg/hr APD418	-2.00	± 2.828
Cohort 2- Placebo	-2.67	± 8.145

PCWP: 2 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-1.50	± 5.000
Cohort 1- Placebo	-3.33	± 1.528
Cohort 2- 0.5 mg/kg/hr APD418	1.56	± 3.609
Cohort 2- Placebo	-0.67	± 7.506

PCWP: 3 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-3.75	± 3.594
Cohort 1- Placebo	-0.33	± 4.509
Cohort 2- 0.5 mg/kg/hr APD418	-3.67	± 3.464
Cohort 2- Placebo	-3.67	± 7.506

PCWP: 4 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-2.75	± 3.948
Cohort 1- Placebo	-0.67	± 5.033
Cohort 2- 0.5 mg/kg/hr APD418	-2.90	± 5.384
Cohort 2- Placebo	-5.00	± 9.165

PCWP: 5 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-0.50	± 6.137
Cohort 1- Placebo	-1.33	± 6.110
Cohort 2- 0.5 mg/kg/hr APD418	-1.56	± 2.698
Cohort 2- Placebo	-3.33	± 9.018

PCWP: 6 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-0.75	± 7.411
Cohort 1- Placebo	-1.67	± 5.686
Cohort 2- 0.5 mg/kg/hr APD418	-1.25	± 2.315
Cohort 2- Placebo	-1.67	± 9.504

RAP: 0.5 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.50	± 1.291
Cohort 1- Placebo	0.00	± 1.732
Cohort 2- 0.5 mg/kg/hr APD418	1.40	± 3.836
Cohort 2- Placebo	-1.33	± 2.517

Part A: Change in Pulmonary Artery Pulsatility Index (PAPi) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours Secondary · Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion

PAPi is a hemodynamic parameter that is derived from right atrial and pulmonary artery pulse pressures. PAPi = (PAS - PAD)/right atrial pressure. Change in PAPi measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure.

PAPi: 0.5 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.28	± 0.411
Cohort 1- Placebo	-0.17	± 0.833
Cohort 2- 0.5 mg/kg/hr APD418	-0.11	± 0.713
Cohort 2- Placebo	0.37	± 1.343

PAPi: 1 hour

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-0.08	± 0.562
Cohort 1- Placebo	0.17	± 0.306
Cohort 2- 0.5 mg/kg/hr APD418	-0.21	± 0.835
Cohort 2- Placebo	-0.17	± 0.603

PAPi: 2 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.38	± 0.435
Cohort 1- Placebo	0.33	± 0.058
Cohort 2- 0.5 mg/kg/hr APD418	-0.14	± 1.011
Cohort 2- Placebo	0.20	± 0.900

PAPi: 3 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.65	± 0.624
Cohort 1- Placebo	0.43	± 0.777
Cohort 2- 0.5 mg/kg/hr APD418	0.03	± 0.897
Cohort 2- Placebo	-0.33	± 0.611

PAPi: 4 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	1.35	± 1.838
Cohort 1- Placebo	0.83	± 1.834
Cohort 2- 0.5 mg/kg/hr APD418	0.27	± 1.203
Cohort 2- Placebo	-1.03	± 0.907

PAPi: 5 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.95	± 0.597
Cohort 1- Placebo	2.33	± 1.818
Cohort 2- 0.5 mg/kg/hr APD418	-0.01	± 0.872
Cohort 2- Placebo	0.87	± 2.639

PAPi: 6 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	0.93	± 0.929
Cohort 1- Placebo	1.27	± 0.929
Cohort 2- 0.5 mg/kg/hr APD418	0.77	± 2.470
Cohort 2- Placebo	-0.90	± 0.173

Part A: Change in Systemic Vascular Resistance Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours Secondary · Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion

Systemic vascular resistance (SVR) is the amount of force exerted on circulating blood by the vasculature of the body. SVR was calculated as 80\*(mean arterial pressure - mean venous pressure) divided by cardiac output. Change in SVR measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure.

SVR: 0.5 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	10.30	± 74.776
Cohort 1- Placebo	-71.27	± 55.492
Cohort 2- 0.5 mg/kg/hr APD418	-47.30	± 139.874
Cohort 2- Placebo	74.13	± 198.427

SVR: 1 hour

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-80.50	± 57.295
Cohort 1- Placebo	-86.30	± 80.694
Cohort 2- 0.5 mg/kg/hr APD418	16.71	± 231.657
Cohort 2- Placebo	-131.93	± 91.886

SVR: 2 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-48.83	± 71.811
Cohort 1- Placebo	-46.23	± 28.762
Cohort 2- 0.5 mg/kg/hr APD418	-42.16	± 205.772
Cohort 2- Placebo	-49.40	± 136.124

SVR: 3 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-67.63	± 56.169
Cohort 1- Placebo	-8.10	± 102.327
Cohort 2- 0.5 mg/kg/hr APD418	-101.20	± 188.863
Cohort 2- Placebo	-195.77	± 101.041

SVR: 4 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	-27.20	± 104.351
Cohort 1- Placebo	73.90	± 136.245
Cohort 2- 0.5 mg/kg/hr APD418	-33.91	± 241.040
Cohort 2- Placebo	-311.03	± 145.094

SVR: 5 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	21.10	± 112.824
Cohort 1- Placebo	132.63	± 171.630
Cohort 2- 0.5 mg/kg/hr APD418	-92.29	± 94.834
Cohort 2- Placebo	-110.57	± 222.498

SVR: 6 hours

Group	Value	95% CI
Cohort 1- 0.17 mg/kg/hr APD418	33.10	± 106.652
Cohort 1- Placebo	90.37	± 137.576
Cohort 2- 0.5 mg/kg/hr APD418	-70.00	± 116.681
Cohort 2- Placebo	-104.23	± 90.537

Adverse events — posted to ClinicalTrials.gov

Time frame: From start of study treatment on Day 1 up to Day 9. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Cohort 1- 0.17 mg/kg/hr APD418

Serious: 0/4 (0%)

Deaths: 0/4

Cohort 1- Placebo

Serious: 0/3 (0%)

Deaths: 0/3

Cohort 2- 0.5 mg/kg/hr APD418

Serious: 0/11 (0%)

Deaths: 0/11

Cohort 2- Placebo

Serious: 0/4 (0%)

Deaths: 0/4

Other adverse events (7 terms — click to expand)

Reaction	System	Cohort 1- 0.17 mg/kg/hr AP…	Cohort 1- Placebo	Cohort 2- 0.5 mg/kg/hr APD…	Cohort 2- Placebo
Haematuria	Renal and urinary disorders	—	—	—	—
Ventricular extrasystoles	Cardiac disorders	—	—	—	—
Fatigue	General disorders	—	—	—	—
N-terminal prohormone brain natriuretic peptide increased	Investigations	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Vein rupture	Vascular disorders	—	—	—	—

Data from ClinicalTrials.gov NCT05139615 adverse events section.

Sponsor's own description

The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science.
Trujillo ME, Ayalasomayajula S, Blaustein RO, Gheyas F. · · 2023 · cited 32× · PMID 37997225 · DOI 10.1111/cts.13677

Verify or expand the search:

Other recruiting trials for Acute Heart Failure With Reduced Ejection Fraction

Currently open trials in the same condition.

NCT06595290 — Vietnamese Rapid Acceleration Protocol for Intensifying Drug Therapy in Heart Failure With Reduced Ejection Fraction · NA · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05139615 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 9 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05139615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing